Biosimilars market set to nearly quadruple in next five years, report finds
Market forecast rosy, though market in United States remains young.
Janssen sees a potential myeloma CAR-T edge, exec says at BIO
The company plans to open its upcoming trial of a Chinese-developed CAR-T at four initial sites later this year.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Experts at BIO, ASCO weigh in on CAR-Ts versus bispecific antibodies
CAR-Ts have generated excitement, but bispecific monoclonal antibodies may continue to have a competitive edge in some cases.
J&J to enter Chinese CAR-T for myeloma into Phase Ib/II trial
The clinical trial of the CAR-T - a potential competitor to bluebird bio's - will start enrolling patients later this year.
FDA: Drugmaker ‘shenanigans’ delaying cheaper competitors and boosting prices
A KHN analysis found that 47 of the drugs cost Medicare and Medicaid almost $12 billion in 2016. The spending totals don’t include rebates, which drugmakers return to the government after paying for the drugs upfront but are not public.
Right-to-try bill passes in House, heads to president’s desk for signature
The legislation, which has drawn criticism from researchers, patient advocates and industry, would enable patients to request experimental drugs while bypassing the FDA.
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Janssen develops mobile clinical trials platform to reduce drug development costs, improve adherence
Janssen's iSTEP platform is part of an ongoing effort by pharma companies to reduce the cost of drug development and address the complexities of having multiple sites for these trials in different countries.
PeptiDream and J&J ink billion-dollar drug discovery deal
Japan's PeptiDream has once again turned small molecules into big business, signing a drug discovery agreement with Johnson & Johnson that could be worth up to $1.15 billion.
StartUp Health and Janssen join forces for healthcare transformation
If you didn't get the digital health memo: incubators and accelerators are out, long-term partnerships and mentorships are in. That's the theory behind StartUp Health's new partnership with J&J's pharma arm, Janssen.
HIV drug ad encourages patient engagement, social media
Janssen Therapeutics is pushing patient engagement, with a touch of social media, for marketing HIV medication Prezcobix.
Maximize Revenue and Patient Care with Strategic Weight Loss Management
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
J&J launches Neuroscience Catalyst to seed academic spinouts
There’s a serious dearth of psychiatric drugs under development, but Janssen is taking a gander at speeding up innovation on that front. The project’s called Neuroscience Catalyst. Over the course of three years, Janssen and Johnson & Johnson Innovation plan to set up 10 research projects that examine mood disorders, Alzheimer’s disease and other neurological conditions. Working […]
Artificial pancreas-maker ViaCyte has new trials, funding, and Janssen partnership
San Diego’s ViaCyte is clearly up to plenty – the regenerative medicine company just announced it has teamed up with Janssen Research & Development, securing $20 million in financing in the process. As part of the deal, the pharma giant gains rights to evaluate clinical efficacy of ViaCyte’s Type 1 diabetes treatment – an artificial […]
Janssen testing mobile health solution to coordinate care for cardiac rehab
The 12 weeks of cardiac rehab that patients who have had heart surgery are prescribed is critical. It can make all the difference in a patient’s outcome. But despite improving referrals and attendance at orientation, participation tends to be on the low side. Janssen Healthcare Innovation is piloting a care coordination program, Care4Today Heart Health Solutions, […]
CONVERGE product demonstration: Janssen Healthcare Innovation
One theory behind improving patient adherence is it’s a question of memory and helping people stay better organized. For people who may be taking several medications at once, missing one or two medication times can lessen the effect of the drug, or negatively impact the person’s health. Johnson & Johnson (NYSE: JNJ) subsidiary Janssen Healthcare […]
Will Janssen’s new class of type 2 diabetes drug fare better than AZN?
Janssen, a division of Johnson & Johnson (NYSE:JNJ) has submitted a new drug application for canagliflozin that belongs to a new class of drugs called SGLT2 inhibitors to treat type 2 diabetes. The drugmaker is surely hoping it fares better than its rivals AstraZeneca (NYSE:AZN) and Bristol-Myers Squibb (NYSE:BMY) since the U.S. Food and Drug […]